Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Magnesium transporter NIPA1 (NIPA1) is a transmembrane protein belonging to the SLC57 family that encodes a magnesium ion transporter with 329 amino acids and nine transmembrane domains. The protein plays a crucial role in regulating cellular magnesium levels, localizes primarily to early endosomes and the plasma membrane in neuronal and epithelial cells, and shows regulated surface expression in response to extracellular magnesium concentrations. NIPA1 also interacts with the type II BMP receptor, inhibiting BMP signaling important for neural development and axonal maintenance. Mutations, particularly polyalanine expansions, in NIPA1 are causative for hereditary spastic paraplegia type 6 and may contribute to amyotrophic lateral sclerosis risk. Extensive evidence points to its importance in normal neurologic development and function, although its direct therapeutic targeting remains investigational.
Not therapeutically exploited to date. Theoretical mechanisms could include modulation of magnesium transport, or pharmacologic inhibition/activation based on inhibitory effect on BMP signaling.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Magnesium transporter NIPA1 (NIPA1).